Skip to main content
DBV Technologies logo

DBV Technologies — Investor Relations & Filings

Ticker · DBV ISIN · FR0010417345 LEI · 969500PVBQFWQKVDMD80 PA Manufacturing
Open in API
Filings indexed 1,040 across all filing types
Latest filing 2026-05-13 Proxy Solicitation & In…
Country FR France
Listing PA DBV

About DBV Technologies

https://www.dbv-technologies.com/

DBV Technologies is a clinical-stage biopharmaceutical company developing treatments for food allergies and other immunological diseases. The company's core technology is Viaskin®, a proprietary investigational platform based on epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to re-educate the immune system by delivering minimal amounts of antigens through intact skin. DBV's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergies in pediatric patients. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, with the platform holding potential for applications beyond food allergies.

Recent filings

Filing Released Lang Actions
Combined General Meeting of June 3, 2026
Proxy Solicitation & Information Statement Classification · 70% confidence The document is a press release announcing the procedures and availability of preparatory materials for the Combined General Meeting on June 3, 2026. It does not present financial results or vote outcomes, nor does it attach the materials themselves, but rather informs shareholders how to obtain the proxy materials and voting instructions. This aligns with a proxy solicitation/information statement category, where materials and notices are provided to shareholders in advance of a vote. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2026-05-13 English
Assemblée Générale Mixte du 3 juin 2026
Regulatory Filings Classification · 70% confidence The document is a press release notifying shareholders of the upcoming Annual General Meeting (AGM) and detailing how to access the preparatory materials. It does not contain the AGM materials themselves, nor is it a formal proxy statement or the AGM report—rather, it’s a regulatory announcement about meeting logistics and disclosure. As such, it falls under the catch-all category for general regulatory filings rather than an AGM materials package (AGM-R), formal proxy statement (PSI), or report publication notice (RPA). Therefore, the correct classification is Regulatory Filings (RNS).
2026-05-13 French
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
Regulatory Filings Classification · 75% confidence The document is a press release announcing DBV Technologies’ participation in an investor conference and providing event and webcast details. It does not contain financial results (so not ER/IR), no detailed presentation content (so not IP), nor other specific transaction or regulatory content. It is essentially a general corporate announcement, which falls into the fallback category for miscellaneous filings. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-12 English
DBV Technologies participera à la 4e édition de la conférence annuelle BioConnect Investor organisée par H.C. Wainwright au Nasdaq
Regulatory Filings Classification · 80% confidence The document is a press release announcing the company’s participation in an upcoming investor conference (a ‘fireside chat’ event), with no substantive financial results, regulatory disclosures, or governance details. It does not include an investor slide deck itself, earnings figures, management discussion, or any formal voting or transaction notices. Therefore, it falls into the generic category for miscellaneous regulatory/press announcements that do not fit other specialized categories.
2026-05-12 French
DBV Technologies publie ses résultats financiers du 1er trimestre 2026
Interim / Quarterly Report Classification · 100% confidence The document is a press release dated April 30, 2026, from DBV Technologies announcing its financial results for the first quarter of 2026. It includes detailed financial data such as revenues, R&D expenses, net loss, cash position, and operational highlights for the quarter ended March 31, 2026. The document also references the approval of the quarterly financial statements by the Board of Directors and discusses business developments and outlook. The length of the document (13,400 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive quarterly financial report rather than a brief announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2026-04-30 French
DBV Technologies Reports First Quarter 2026 Financial Results
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated April 30, 2026, reporting the first quarter 2026 financial results of DBV Technologies. It includes detailed financial data such as cash position, net loss, operating income, expenses, and a condensed consolidated statement of operations for the three months ended March 31, 2026. The document also discusses operational highlights, business strategy, and forward-looking statements. The presence of unaudited condensed consolidated financial statements and detailed financial performance for a quarter indicates this is a quarterly financial report. The document length is 11,477 characters, which is substantial and contains actual financial data, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2026-04-30 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.